SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elanco Animal Health Incorporated due to allegations of misleading statements regarding product safety and approval timelines, which have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elanco between November 7, 2023, and June 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elanco, with a deadline of December 6, 2024, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Elanco and its executives violated federal securities laws by making false statements about the safety of Zenrelia and the timelines for FDA approval of Zenrelia and Credelio Quattro [4]. Group 2: Product Safety and Approval Issues - Elanco's press release on June 27, 2024, indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and limit treatment days by approximately 25$3.70 per share, or 20.59%, closing at $14.27 per share on June 27, 2024 [6].